Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Approaches to Malnutrition Enteropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 6 - 59 months, of either sex;~2. Inpatient in the paediatric wards of one of the research sites;~3. Hospitalised with Severe Acute Malnutrition (SAM, defined using WHO definition: weight-for-length z score of less than -3, or mid upper arm circumference of less than 11.5cm, and/or bilateral pedal oedema);~4. Clinically stable\*;~5. With written, informed consent from the primary caregiver(s); the child cannot be enrolled if the primary caregiver(s) cannot give consent.~   * Judged by the medical team on a case by case basis, but in general a child without shock, hypothermia, hypoglycaemia or reduced conscious level.~Exclusion Criteria:~1. Clinically unstable\*;~2. Less than 5kg body weight;~3. Neurological disability which would explain or partly explain poor feeding;~4. Oro-facial abnormalities which would explain or partly explain poor feeding;~5. Caregiver unwilling to consent to child HIV testing;~6. Haemoglobin concentration \< 6 g/dl at the time of enrolment;~7. Caregiver unwilling to remain in hospital for the duration of the study treatment;~8. Any underlying condition, other than HIV, which in the opinion of the investigator would put the subject at undue risk of failing study completion or would interfere with analysis of study results;~9. Contraindication to any of the trial treatments (e.g. allergy to cow's milk protein).~   * As assessed by the medical team on a case-by-case basis, but in general a clinically unstable state would include shock, hypothermia, hypoglycaemia or reduced conscious level.

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 59 Months
- Healthy Volunteers: f

Study Arms:
- Colostrum (Type: EXPERIMENTAL): Colostrum high protein powder (Neovite) given orally or through NG tube 1.5g daily, in addition to standard care following WHO guidelines for management of SAM.
- GInNAC (Type: EXPERIMENTAL): N-Acetyl glucosamine (GInNAC). Given orally (1g three times daily) for 14 days, gradually increased from 0.5g to avoid osmotic diarrhoea, in addition to standard care following WHO guidelines for management of SAM.
- Teduglutide (Type: EXPERIMENTAL): Teduglutide s/c. Administration by subcutaneous injection (0.5mg/kg/day) daily for 14 days, in addition to standard care following WHO guidelines for management of SAM.
- Budenoside (Type: EXPERIMENTAL): Budesonide 3mg orally daily for 14 days, then rapidly tapered, in addition to standard care following WHO guidelines for management of SAM.
- Standard care (Type: NO_INTERVENTION): Standard care following WHO guidelines for management of SAM.

Based on this trial design, predict the completion outcome and termination type (if applicable).